• Event Type: Q4 and FY26 Earnings Conference Call with analysts and investors.
  • Event Date and Time: Held on May 25, 2026. The specific time was not disclosed in the transcript.
  • Purpose of Event: Discussion of financial results for the quarter and financial year ended March 31, 2026, and providing a strategic business update.
  • Management Participants: Mr. Shiven Arora – Managing Director; Mr. VK Singh – Chief Operating Officer; Mr. Ganesh Karuppannan – Chief Financial Officer; Mr. Sanjay Sinha – Deputy Chief Financial Officer.
  • Availability of Materials: The investor presentation and financial results were available on the company website and stock exchanges. The audio recording and transcript of the conference call were made available on the company website (https://bluejethealthcare.com/investor-presentation/) and the exchanges.
  • UPSI Statement: The moderator's opening remarks included standard forward-looking statement cautions, but no explicit statement confirming that no Unpublished Price Sensitive Information (UPSI) would be shared was made in the provided transcript.

Financial Period Discussed: The call primarily discussed the financial results for Q4 FY26 (quarter ended March 31, 2026) and the full financial year FY26 (year ended March 31, 2026).

Forward-Looking Statements & Strategic Themes:

  • FY27 Contrast Media Outlook: Management expects double-digit growth in this segment, supported by customer forecasts and 3-4 new product launches.
  • FY27 PI/API Outlook: The segment is expected to normalize and grow above the FY25 peak revenue of ~INR460 crore, as customer destocking is complete and orders have been received.
  • Expansion Projects: A significant capex of ~INR400 crore is planned for FY27 towards the Vizag greenfield project (total envisaged capex ~INR1,000 cr), completion of the Mahad Unit 3 backward integration project, and other additions at Ambernath. The Mahad project is expected to commence production in H2 FY27.
  • R&D Focus: The new Hyderabad R&D center (investment of ~INR40 cr) will focus on newer chemistry platforms including peptide intermediates and GLP-1 linked opportunities.
  • Pipeline: The company is tracking ~20 active RFPs in the PI/CDMO segment, with 2 expected to commercialize in FY27. It is also evaluating 2 high-conviction lateral entry opportunities for which dedicated capacity is being planned at Vizag.

Additional Notes Section

  • The document provided is the transcript of the earnings call, filed with the exchanges pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.
  • The transcript contains detailed financial data for FY26 and Q4 FY26, including segmental revenue breakdowns, margins, and other income figures.

Tagging: